Advances in the treatment of intermediate and posterior uveitis

References

• Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am. J. Ophthalmol.140, 509–516 (2005).
   PubMed Web of Science ®Google Scholar
• Bloch-Michel E, Nussenblatt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am. J. Ophthalmol.103, 234–235 (1987).
   PubMed Web of Science ®Google Scholar
• Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br. J. Ophthalmol.80, 332–336 (1996).
   PubMed Web of Science ®Google Scholar
• Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br. J. Ophthalmol.80, 844–848 (1996).
   PubMed Web of Science ®Google Scholar
• Konstantopoulou M, Belgi A, Griffiths K, Seale J, Macfarlane A. Azathioprine-induced pancytopenia in a patient with pompholyx and deficiency of erythrocyte thiopurine methyltransferase. Br. Med. J.330, 350–351 (2005).
   PubMed Web of Science ®Google Scholar
• Yazici H, Pazarli H, Barnes CG et al. A controlled trial of azathioprine in Behçet’s syndrome. N. Engl. J. Med.322, 281–285 (1990).
   PubMed Web of Science ®Google Scholar
• Vianna RN, Ozdal PC, Deschenes J. Burnier MN Jr. Combination of azathioprine and corticosteroids in the treatment of serpiginous choroiditis. Can. J. Ophthalmol.41, 183–189 (2006).
   PubMed Web of Science ®Google Scholar
• Moore CE. Sympathetic ophthalmitis treated with azathioprine. Br. J. Ophthalmol.52, 688–690 (1968).
   PubMed Web of Science ®Google Scholar
• Becker MD. Wertheim MS.Smith JR. Rosenbaum JT. Long-term follow-up of patients with birdshot retinochoroidopathy treated with systemic immunosuppression. Ocul. Immunol. Inflamm.13, 289–293 (2005).
   PubMed Web of Science ®Google Scholar
• Kiss S, Ahmed M, Letko E, Foster CS. Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy. Ophthalmology112, 1066–1071 (2005).
   PubMed Web of Science ®Google Scholar
• Paredes I, Ahmed M, Foster CS. Immunomodulatory therapy for Vogt–Koyanagi–Harada patients as first-line therapy. Ocul. Immunol. Inflamm.14, 87–90 (2006).
   PubMed Web of Science ®Google Scholar
• Rao NA. Treatment of Vogt–Koyanagi– Harada disease by corticosteroids and immunosuppressive agents. Ocul. Immunol. Inflamm.14, 71–72 (2006).
   PubMed Web of Science ®Google Scholar
• Agarwal M, Ganesh SK, Biswas J. Triple agent immunosuppressive therapy in Vogt–Koyanagi–Harada syndrome. Ocul. Immunol. Inflamm.14, 333–339 (2006).
   PubMed Web of Science ®Google Scholar
• Allison AC, Eugui EM. Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol. Rev.136, 5–28 (1993).
   PubMed Web of Science ®Google Scholar
• Böhm M, Beissert S, Schwarz T et al. Bullous pemphigoid treated with mycophenolate mofetil. Lancet349, 541 (1997).
   PubMed Web of Science ®Google Scholar
• Enk AH, Knop J. Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet350, 494 (1997).
   PubMed Web of Science ®Google Scholar
• Goldblum R. Therapy of rheumatoid arthritis with mycophenolate mofetil. Clin. Exp. Rheumatol.11(Suppl. 8), S117–S119 (1993).
   PubMed Web of Science ®Google Scholar
• Adu D, Cross J, Jayne DR. Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus10, 203–208 (2001).
   PubMed Web of Science ®Google Scholar
• Meihsler W, Reinisch W, Moser G et al. Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn’s disease? Am. J. Gastroenterol.96, 782–787 (2001).
   PubMed Web of Science ®Google Scholar
• Siepmann K, Huber M, Stubiger N, Deuter C, Zierhut M. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis: a retrospective analysis of 106 patients. Graefes Arch. Clin. Exp. Ophthalmol.244, 788–794 (2006).
   PubMed Web of Science ®Google Scholar
• Kilmartin DJ, Forrester JV, Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet352, 35–36 (1998).
   PubMed Web of Science ®Google Scholar
• Larkin G, Lightman S. Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology218, 222–228 (1999).
   Google Scholar
• Lau CH, Comer M, Lightman S. Long-term efficacy of mycophenolate mofetil in the control of severe intraocular inflammation. Clin. Exp. Ophthalmol.31, 487–491 (2003).
   PubMed Web of Science ®Google Scholar
• Zierhut M, Stübiger N, Aboalchamat W et al. Immunosuppressive treatment with mycophenolate mofetil (CellCept) in the therapy of uveitis. Ophthalmologe98, 647–651 (2001).
   PubMed Web of Science ®Google Scholar
• Maini R, Clair EW, St Breedveld F, Furst D, Kalden J, Weisman M; ATTRACT Study Group. Infliximab (chimeric anti-tumor necrosis factor a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized Phase III trial. Lancet354, 1932–1939 (1999).
   PubMed Web of Science ®Google Scholar
• Lipsky PE, van der Heijde DM, Clair EW, St Furst DE, Breedveld FC, Kalden JR; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N. Engl. J. Med.343, 1594–602 (2000).
   PubMed Web of Science ®Google Scholar
• Gerloni V, Pontikaki I, Gattinara M, Desiati F, Lupi E, Lurati A. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor a monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum.52, 548–553 (2005).
   PubMed Web of Science ®Google Scholar
• Levälampi T, Honkanen V, Lahdenne P, Nieminen R, Hakala M, Moilanen E. Effects of infliximab on cytokines, myeloperoxidase, and soluble adhesion molecules in patients with juvenile idiopathic arthritis. Scand. J. Rheumatol.36, 189–193 (2007).
   PubMed Web of Science ®Google Scholar
• Murphy CC, Duncan L, Forrester JV, Dick AD. Systemic CD4+ T cell phenotype and activation status in intermediate uveitis. Br. J. Ophthalmol.88, 412–416 (2004).
   PubMed Web of Science ®Google Scholar
• De Vos AF, Van Haren MA, Verhagen C, Hoekzema R, Kijlstra A. Systemic anti-tumor necrosis factor antibody treatment exacerbates endotoxin-induced uveitis in the rat. Exp. Eye Res.61, 667–675 (1995).
   PubMed Web of Science ®Google Scholar
• Shen DF, Buggage RR, Eng HC, Chan CC. Cytokine gene expression in different strains of mice with endotoxin-induced uveitis (EIU). Ocul. Immunol. Inflamm.8, 221–225 (2000).
   PubMed Web of Science ®Google Scholar
• Santos Lacomba M, Marcos Martin C, Gallardo Galera JM et al. Aqueous humor and serum tumor necrosis factor-α in clinical uveitis. Ophthalmic Res.33, 251–255 (2001).
   PubMed Web of Science ®Google Scholar
• Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology110, 1449–1453 (2003).
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N. Engl. J. Med.345, 1098–1104 (2001).
   PubMed Web of Science ®Google Scholar
• Fonollosa A, Segura A, Giralt J. Garcia-Arumi J. Tuberculous uveitis after treatment with etanercept. Graefes Arch. Clin. Exp. Ophthalmol.245, 1397–1399 (2007).
   PubMed Web of Science ®Google Scholar
• British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax60, 800–805 (2005).
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Iqbal I, Nandeshwar P et al. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Safety25, 173–197 (2002).
   PubMed Web of Science ®Google Scholar
• Al-Rayes H, Al-Swailem R, Al-Balawi M, Al-Dohayan N, Al-Zaidi S, Tariq M. Safety and efficacy of infliximab therapy in active behcet’s uveitis: an open-label trial. Rheumatol. Int. (2008) (Epub ahead of print).
   PubMedGoogle Scholar
• Ardoin SP, Kredich D, Rabinovich E, Schanberg LE, Jaffe GJ. Infliximab to treat chronic noninfectious uveitis in children: retrospective case series with long-term follow-up. Am. J. Ophthalmol.144, 844–849 (2007).
   PubMed Web of Science ®Google Scholar
• Richards JC, Tay-Kearney ML, Murray K, Manners P. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin. Exp. Ophthalmol.33, 461–468 (2005).
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet’s disease. Int. Ophthalmol.26, 83–92 (2005).
   PubMedGoogle Scholar
• Benitez-del-Castillo JM, Martinez-de-la-Casa JM, Pato-Cour E et al. Long-term treatment of refractory posterior uveitis with anti-TNFα (infliximab). Eye19, 841–845 (2005).
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Mudun A, Urgancioglu M et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet’s disease: an open-label trial. Arthritis Rheum.52, 2478–2484 (2005).
   PubMed Web of Science ®Google Scholar
• Wechsler B, Sable-Fourtassou R, Bodaghi B et al. Infliximab in refractory uveitis due to Behcet’s disease. Clin. Exp. Rheum.22(4 Suppl. 34), S14–S16 (2004).
   PubMed Web of Science ®Google Scholar
• Giansanti F, Barbera ML, Virgili G, Pieri B, Emmi L, Menchini U. Infliximab for the treatment of posterior uveitis with retinal neovascularization in Behcet disease. Eur. J. Ophthalmol.14, 445–448 (2004).
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Theodossiadis PG, Katsiari CG et al. Effect of infliximab on sight-threatening panuveitis in Behcet’s disease. Lancet358, 295–296 (2001).
   PubMed Web of Science ®Google Scholar
• Niccoli L, Nannini C, Benucci M et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease: a 24-month follow-up study. Rheumatology46, 1161–1164 (2006).
   Web of Science ®Google Scholar
• Markomichelakis NN, Theodossiadis PG, Pantelia E, Papaefthimiou S, Theodossiadis GP, Sfikakis PP. Infliximab for chronic cystoid macular edema associated with uveitis. Am. J. Ophthalmol.138, 648–650 (2004).
   PubMed Web of Science ®Google Scholar
• Reiff A. Long-term outcome of etanercept therapy in children with treatment-refractory uveitis. Arthritis Rheum.48, 2079–2080 (2003).
   PubMedGoogle Scholar
• Smith JA, Thompson DJ, Whitcup SM et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum.53, 18–23 (2005).
   PubMed Web of Science ®Google Scholar
• Foster CS. Tufail F.Waheed NK et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch. Ophthalmol.121, 437–440 (2003).
   PubMed Web of Science ®Google Scholar
• Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology44, 1008–1011 (2005).
   PubMed Web of Science ®Google Scholar
• Hashkes PJ. Shajrawi I. Sarcoid-related uveitis occurring during etanercept therapy. Clin. Exp. Rheum.21, 645–646 (2003).
   PubMed Web of Science ®Google Scholar
• Reddy AR. Backhouse OC. Does etanercept induce uveitis?. Br. J. Ophthalmol.87, 925 (2003).
   PubMed Web of Science ®Google Scholar
• Saurenmann RK, Levin AV, Feldman BM, Laxer RM, Schneider R, Silverman ED. Risk of new-onset uveitis in patients with juvenile idiopathic arthritis treated with anti-TNFα agents. J. Pediatr.149, 833–836 (2006).
   PubMed Web of Science ®Google Scholar
• Tynjälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann. Rheum. Dis.66, 548–550 (2007).
   PubMed Web of Science ®Google Scholar
• Foeldvari I, Nielsen S, Kummerle-Deschner J et al. Tumor necrosis factor-α blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey. J. Rheumatol.34, 1146–1150 (2007).
   PubMed Web of Science ®Google Scholar
• Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum.52, 2447–2451 (2005).
   PubMed Web of Science ®Google Scholar
• Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J. Pediatr.149, 572–575 (2006).
   PubMed Web of Science ®Google Scholar
• Biester S, Deuter C, Michels H et al. Adalimumab in the therapy of uveitis in childhood. Br. J. Ophthalmol.91, 319–324 (2007).
   PubMed Web of Science ®Google Scholar
• Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behcet’s disease. Eye21, 824–825 (2007).
   PubMed Web of Science ®Google Scholar
• Guex-Crosier Y, Raber J, Chan CC et al. Humanized antibodies against the α-chain of the IL-2 receptor and against the β-chain shared by the IL-2 and IL-15 receptors in a monkey uveitis model of autoimmune diseases. J. Immunol.158, 452–458 (1997).
   PubMed Web of Science ®Google Scholar
• Buggage RR, Levy-Clarke G, Sen HN et al. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behcet’s disease. Ocul. Immunol. Inflamm.1, 63–70 (2007).
   Google Scholar
• Nussenblatt RB, Peterson JS, Foster CS et al. Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology112, 764–770 (2005).
   PubMed Web of Science ®Google Scholar
• Koetter I, Eckstein AK, Stuebiger N, Zierhut M. Treatment of ocular symptoms of Behçet’s disease with interferon α2a: a pilot study. Br. J. Ophthalmol.82, 488–494 (1998).
   PubMed Web of Science ®Google Scholar
• Wechsler B, Bodaghi B, Huong DL et al. Efficacy of interferon α-2a in severe and refractory uveitis associated with Behçet’s disease. Ocul. Immunol. Inflamm.8, 293–301 (2000).
   PubMed Web of Science ®Google Scholar
• Deuter CME, Koetter I, Guenaydin I, Zierhut M, Stuebiger N. Ocular involvement in Behçet’s disease: first 5-year-results for visual development after treatment with interferon α-2a. Ophthalmologe101, 129–134 (2004).
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Guney-Tefekli E, Urgancioglu M. Results of interferon-α therapy in patients with Behcet uveitis. Graefes Arch. Clin. Exp. Ophthalmol.244, 1692–1695 (2006).
   PubMed Web of Science ®Google Scholar
• Plskova J, Greiner K, Forrester JV. Interferon-α as an effective treatment for noninfectious posterior uveitis and panuveitis. Am. J. Ophthalmol.144, 55–61 (2007).
   PubMed Web of Science ®Google Scholar
• Bodaghi B, Gendron G, Wechsler B et al. Efficacy of interferon a in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br. J. Ophthalmol.91, 335–339 (2007).
   PubMed Web of Science ®Google Scholar
• Deuter CM, Koetter I, Guenaydin I, Stuebiger N, Zierhut M. Interferon α-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina26, 786–791 (2006).
   PubMed Web of Science ®Google Scholar
• Becker MD. Heiligenhaus A. Hudde T et sal. Interferon as a treatment for uveitis associated with multiple sclerosis. Br. J. Ophthalmol.89, 1254–1257 (2005).
   PubMed Web of Science ®Google Scholar
• Sobaci G, Bayraktar Z, Bayer A. Interferon α-2a treatment for serpiginous choroiditis. Ocul. Immunol. Inflamm.13, 59–66 (2005).
   PubMed Web of Science ®Google Scholar
• Lightman S, Towler HMA. Assessment and medical management of posterior uveitis and its complication. In: Uveitis Lightman (Ed.). BMJ Books, London, UK, 119–135 (1998).
   Google Scholar
• Kramer M, Ehrlich R, Snir M et al. Intravitreal injections of triamcinolone acetonide for severe vitritis in patients with incomplete Behcet’s disease. Am. J. Ophthalmol.138, 666–667 (2004).
   PubMed Web of Science ®Google Scholar
• Kok H, Lau C, Maycock N et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology112, 1916–1921 (2005).
   PubMed Web of Science ®Google Scholar
• Kramer M, Ehrlich R, Snir M et al. Intravitreal injections of triamcinolone acetonide for severe vitritis in patients with incomplete Behcet’s disease. Am. J. Ophthalmol.138, 666–667 (2004).
   PubMed Web of Science ®Google Scholar
• Karacorlu M, Mudun B, Ozdemir H et al. Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behcet disease. Am. J. Ophthalmol.138, 289–291 (2004).
   PubMed Web of Science ®Google Scholar
• Young S, Larkin G, Branley M, Lightman S. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin. Exp. Ophthalmol.29, 2–6 (2001).
   PubMed Web of Science ®Google Scholar
• Antcliff RJ, Spalton DJ, Stanford MR et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology108, 765–772 (2001).
   PubMed Web of Science ®Google Scholar
• Angunawela RI, Heatley CJ, Williamson TH et al. Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: longterm management and outcome. Acta Ophthalmol. Scand.83, 595–599 (2005).
   PubMedGoogle Scholar
• Androudi S, Letko E, Meniconi M et al. Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul. Immunol. Inflamm.13, 205–212 (2005).
   PubMed Web of Science ®Google Scholar
• Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology112, 593–598 (2005).
   PubMed Web of Science ®Google Scholar
• Galor A, Margolis R, Brasil OM et al. Adverse events after intravitreal triamcinolone in patients with and without uveitis. Ophthalmology114, 1912–1918 (2007).
   PubMed Web of Science ®Google Scholar
• Jafee GJ, Martin D, Callanan D, Pearson PA, Levy B, Comstock T; Fluocinolone Acetonide Uveitis Study Group. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology113, 1020–1027 (2006).
   PubMed Web of Science ®Google Scholar
• Kuppermann BD, Blumenkranz MS, Haller JA et al. Dexamethasone DDS Phase II Study Group; Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema. Arch. Ophthalmol.125, 309–317 (2007).
   PubMed Web of Science ®Google Scholar
• Mackensen F, Heinz C, Becker MD, Heiligenhaus ARND. Intravitreal bevacizumab (Avastin) as a treatment for refractory macular edema in patients with uveitis: a pilot study. Retina28, 41–45 (2008).
   PubMed Web of Science ®Google Scholar